Clinical utility of secukinumab in moderate-to-severe scalp psoriasis: evidence to date

Psoriasis is an immune-mediated inflammatory dermatosis commonly affecting the scalp and fringes of the face, neck and ears. It may be difficult to treat and the presence of extensive and highly visible lesions may significantly influence psychosocial well-being. Secukinumab, a monoclonal antibody t...

Full description

Saved in:
Bibliographic Details
Published inClinical, cosmetic and investigational dermatology Vol. 12; pp. 249 - 253
Main Authors Kivelevitch, Dario, Amin, Sima, Menter, Alan
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.04.2019
Taylor & Francis Ltd
Dove
Dove Medical Press
Subjects
Adalimumab
Antibodies
Apremilast
Dermatologic agents
Guselkumab
Interleukins
Ixekizumab
Monoclonal antibodies
Psoriasis
Review
scalp
Secukinumab
therapy
Ustekinumab
psoriasis
scalp
therapy
secukinumab
Online AccessGet full text

Cover

More Information
Summary:Psoriasis is an immune-mediated inflammatory dermatosis commonly affecting the scalp and fringes of the face, neck and ears. It may be difficult to treat and the presence of extensive and highly visible lesions may significantly influence psychosocial well-being. Secukinumab, a monoclonal antibody that selectively targets interleukin-17A and has been shown to provide robust and sustained efficacy for whole body psoriasis. In this review, we evaluate the evidence to date of secukinumab in patients with moderate-to-severe scalp psoriasis. A comprehensive Cochrane database and PubMed searches of all available literature in English through September 2018 was performed using the search terms: "psoriasis", "scalp" and "secukinumab". Based on current evidence, we conclude that secukinumab is efficacious and well-tolerated treatment for patients with moderate-to-severe scalp psoriasis. Further studies are however warranted.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1178-7015
1178-7015
DOI:10.2147/CCID.S165040